Abbott Laboratories (NYSE:ABT) shares jump after a broad-based quarterly beat across medical devices, diagnostics, and ...
Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...
On Jan. 24, Abbott posted its year-end and fourth-quarter numbers for the last three months of 2023. Revenue in Q4 rose by 1.5% year over year to $10.2 billion, but on an organic basis and when ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The North Chicago company said ...
Freenome (FRNM) and Abbott Laboratories (ABT) said Monday that the US Food and Drug Administration approved SimpleScreen CRC, a blood-based colorectal cancer screening test. The c ...
Abbott Laboratories stock rose 8% Wednesday and was the second biggest gainer on the S&P 500 index, after the diagnostics and medical-device company beat earnings estimates for the first quarter. As ...
Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories is rebounding from last year’s manufacturing ...
Abbott Laboratories saw a big jump in demand for its diabetes products in the first quarter, which helped the medical-device company extend its long streak of earnings beats and propelled the stock to ...
Shares of Abbott Laboratories popped after the company's earnings and revenue topped Wall Street estimates, defying a dramatic slowdown in sales of its Covid tests. The results were driven in part to ...
Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results